AnchorDx’s UriFind Deemed a Breakthrough Device

AnchorDx’s noninvasive bladder cancer early detection test, UriFind, has received a Breakthrough Device designation from the FDA.

The Guangzhou, China-based developer claims UriFind works as well as cystoscopy and significantly better than other methods of detecting early and nonmuscle-invasive bladder cancer, such as examining cells in urine under a microscope.

The test, which detects bladder cancer by assessing DNA methylation changes in urine samples, has already earned a CE mark certification in Europe.